Zhu Li, Zhaohui Zhu, Fang Li. Advances of small-molecule protein kinase inhibitor-based PET tracers with prospective application in pancreatic cancer[J]. Int J Radiat Med Nucl Med, 2015, 39(1): 45-49. DOI: 10.3760/cma.j.issn.1673-4114.2015.01.010
Citation: Zhu Li, Zhaohui Zhu, Fang Li. Advances of small-molecule protein kinase inhibitor-based PET tracers with prospective application in pancreatic cancer[J]. Int J Radiat Med Nucl Med, 2015, 39(1): 45-49. DOI: 10.3760/cma.j.issn.1673-4114.2015.01.010

Advances of small-molecule protein kinase inhibitor-based PET tracers with prospective application in pancreatic cancer

  • Pancreatic cancer is one of the most common malignancies of digestive tract. The targeted therapeutic drugs and specific diagnostic probes for pancreatic cancer include antibodies, affinity ligands, polypeptides, and small-molecule protein kinase inhibitors. The research on small-molecule protein kinase inhibitors is a hot topic of both preclinical research and clinical application in recent years. The advances in this area were briefly reviewed in this article. Data indicated that H-89, a kind of isoquinoline sulfonamide small molecule, might be one of the best small-molecule protein kinase inhibitors to treat pancreatic cancer, and if labeled with positron emitter, it might become a potential PET tracer for pancreatic cancer.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return